Open access
Oct 2026
A budget impact analysis for the addition of rare disease genes to secondary findings screening during genome-wide sequencing.
The addition of new rare diseases treatable with targeted drug therapies to the ACMG SF list may result in a significant number of cases diagnosed each year, and the budget impact of these findings should be considered when considering expanding access to GWS.
Nicola Kopac, Nick Dragojlovic, Elisabet Rodriguez Llorian et al.
· Genetics in Medicine · 0 citations